Bristol Orencia launch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb plans to launch its rheumatoid arthritis biologic Orencia (abatacept) in early 2006, the firm says during its third-quarter earnings call Oct. 28. The company expects approval "soon"; FDA extended its Oct. 1 user fee date by 90 days due to complex chemistry, manufacturing and controls sections of the BLA (1Pharmaceutical Approvals Monthly September 2005, In Brief). A full-scale launch will not be possible until FDA approves a third-party manufacturing facility; BMS plans to file an sBLA for the facility post-approval. FDA's Arthritis Drugs Advisory Committee unanimously recommended the first-in-class T-cell co-stimulation modulator for approval Sept. 6...
You may also be interested in...
Bristol Orencia review extension
FDA's revised user fee date for Bristol-Myers Squibb's rheumatoid arthritis biologic Orencia (abatacept) is Dec. 29, Bristol says Sept. 6 after the Arthritis Drugs Advisory Committee's unanimous recommendation for approval. The 90-day extension of the original Oct. 1 action date for the T-cell costimulation modulator was "due to the complexity of the chemistry and manufacturing controls section of the application," BMS says, adding that it plans to file an sBLA for a second Orencia manufacturing facility "at the earliest possible date following BLA approval." Bristol appears to be setting the stage to differentiate Orencia from the RA-approved tumor necrosis factor inhibitors (Humira, Enbrel and Remicade). During the advisory committee meeting, the firm suggested that abatacept interferes earlier than the TNF agents in RA pathogenesis and as a result may have a broader mechanism of action...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.